BioMarin Pharmaceutical Bets on Amicus Growth as VOXZOGO Competition Concerns Mount

BioMarin Pharmaceutical logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • BioMarin forecasts $3.8 billion to $3.9 billion in 2026 revenue, about 20% growth at the midpoint, and expects operational EPS to more than double over three years. The Amicus acquisition adds rare-disease medicines, with BioMarin projecting higher peak sales for GALAFOLD and POMBILITI/OPFOLDA and targeting roughly 60% operating margins by decade’s end through synergies.
  • Executives said concerns about VOXZOGO competition are overstated: U.S. revenue from the currently contested achondroplasia use is 6% of total company revenue, while 75% of VOXZOGO sales come from outside the U.S. BioMarin is pursuing additional indications and expects Phase 2 data for its long-acting BMN 333 in 2027.
  • A large international customer shifted some fourth-quarter orders into early 2027, prompting a guidance adjustment that BioMarin described as a timing issue. The company also highlighted pipeline programs including BMN 820, whose Phase 3 results are expected in 2028.
  • MarketBeat previews top five stocks to own in December.

BioMarin Pharmaceutical NASDAQ: BMRN is betting that a growing rare-disease pipeline and its integration of Amicus will help sustain growth, as executives seek to address investor concerns about competition for its VOXZOGO treatment.

The company expects revenue of $3.8 billion to $3.9 billion in 2026, representing approximately 20% growth at the midpoint. Chief Financial Officer Brian Mueller said revenue is on track to increase about 60% over three years, while operational earnings per share, excluding acquisition-related in-process research and development charges, are on track to more than double over the same period.

Mueller said operating cash flow increased more than fivefold from 2023 to 2025, helping fund the Amicus acquisition, which closed in April. The deal added GALAFOLD for Fabry disease and POMBILITI and OPFOLDA for Pompe disease to BioMarin’s portfolio.

Amicus integration and financial outlook

Mueller said BioMarin added patients to both acquired therapies during the third quarter, its first quarter of combined-company results. The company sees peak revenue of $1.4 billion for GALAFOLD and $1.2 billion for POMBILITI and OPFOLDA, respectively—approximately 40% and 20% above prior peak-revenue views.

BioMarin has identified synergies equal to more than 50% of non-GAAP operating costs in the combined business, Mueller said. With those savings, the company expects the Amicus business to generate operating margins of approximately 60% on BioMarin’s platform by the end of the decade.

Mueller also addressed a guidance adjustment, saying a large international customer deferred some orders planned for the fourth quarter to early 2027. He characterized the change as a timing shift, but said it came too late in the year for BioMarin to easily offset it.

VOXZOGO competition and pipeline plans

A BioMarin executive identified in the transcript only as Alexander said concerns about competition for VOXZOGO have been “blown out of context.” He said U.S. revenue from VOXZOGO for achondroplasia, the indication currently facing competition, represents 6% of BioMarin’s total revenue. The company does not expect to lose that business, he said.

Alexander added that 75% of VOXZOGO revenue comes from outside the United States. BioMarin is also awaiting a U.S. Food and Drug Administration decision on VOXZOGO for hypochondroplasia and has submitted the application in Europe.

Among the company’s pipeline programs is BMN 333, a long-acting treatment being developed for achondroplasia and hypochondroplasia. Phase 2 patient data are expected in 2027. Alexander said BioMarin’s goal is to demonstrate superiority, while noting that the company could consider another development path after reviewing the results.

“Our plan A, plan B, plan C is superiority,” he said, adding that a one-sided non-inferiority study could be an option.

BioMarin also highlighted BMN 440, an oral candidate for hypophosphatasia acquired through its Alesta deal, and BMN 450, a potential subcutaneous treatment for Fabry disease. Alexander said the company hopes BMN 450 could address a larger patient population than GALAFOLD.

For BMN 820, a phase 3 candidate for focal segmental glomerulosclerosis acquired with Amicus, Alexander said the study is fully enrolled and results are expected in 2028. He described the asset as a potential bonus to a transaction that BioMarin believed it could justify based on the acquired commercial medicines and cost synergies.

About BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company's marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in BioMarin Pharmaceutical Right Now?

Before you consider BioMarin Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.

While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines